Beijing Tongrentang Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St · 09/01 00:17

Beijing Tongrentang (SHSE:600085) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥4.50b (down 2.6% from 2Q 2023).
  • Net income: CN¥445.1m (down 3.9% from 2Q 2023).
  • Profit margin: 9.9% (in line with 2Q 2023).
  • EPS: CN¥0.32 (down from CN¥0.34 in 2Q 2023).
earnings-and-revenue-history
SHSE:600085 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Tongrentang Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Beijing Tongrentang (of which 1 is significant!) you should know about.